Dry age-related macular degeneration (AMD) management is currently based on regular follow-up for early detection of choroidal neovascularization (CNV), addressing the risk factors and prescribing ...

Age-related macular degeneration (AMD) is the leading cause of blindness in the West. Delays in injections can cause ...

Macular degeneration, particularly age-related macular degeneration (AMD), is a leading cause of vision loss worldwide. This condition affects the central part of the retina, known as the macula, ...

Discover more about how a common diabetes drug can reduce the incidence of intermediate age-related macular degeneration.

Share on Pinterest The FDA has approved biosimilars for macular degeneration treatment. recep-bg/Getty Images The FDA approved two biosimilars for Eylea (aflibercept), a drug used to treat age-related ...

Enrollment spans Europe, the US, and Canada, targeting ~324 GA patients in a randomized, double-masked, sham-controlled phase 2 program. Dosing compares two intravitreal dose levels given every 12 or ...

Every last Sunday of September marks World Retinitis Pigmentosa (RP) Day, a day dedicated to raising awareness and accelerating efforts to find a cure for this rare, inherited retinal disease ...

Cedars-Sinai investigators working to optimize a cell-based treatment for retinitis pigmentosa have uncovered how ...

Age-related macular degeneration (AMD) is the most common form of irreversible blindness in developed countries. AMD is a complex genetic disease, meaning several genes must be involved. Scientists ...

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety with preliminary assessments of visual and retinal functional outcomes.